| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 1.1% | $63,190 | 702,106 | Nantahala Capital Management, LLC | 30 Sep 2024 | |||
| PERCEPTIVE ADVISORS LLC | 16% | $22,174 | 255,750 | Perceptive Advisors LLC | 12 Aug 2025 |
As of 30 Sep 2025, 0 institutional investors reported holding 0 shares of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA). This represents 0% of the company’s total 1,644,695 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 0 | $0 | -$26 | $0.09 | 0 |
| 2025 Q2 | 300 | $26 | -$3,198,056 | $0.09 | 1 |
| 2025 Q1 | 25,592,846 | $3,229,183 | -$198,660 | $0.13 | 55 |
| 2024 Q4 | 26,880,629 | $5,543,705 | -$1,490,558 | $0.21 | 52 |
| 2024 Q3 | 32,527,603 | $8,360,258 | -$117,730 | $0.26 | 60 |
| 2024 Q2 | 32,730,111 | $9,057,542 | -$110,888,115 | $0.28 | 50 |
| 2024 Q1 | 45,559,346 | $283,375,342 | +$20,623,317 | $6.22 | 78 |
| 2023 Q4 | 16,737 | $87,702 | +$87,702 | $5.24 | 1 |
| 2023 Q3 | 31,928,716 | $124,842,063 | -$8,075,975 | $3.91 | 44 |
| 2023 Q2 | 33,698,803 | $138,396,240 | +$60,941,198 | $4.11 | 38 |
| 2023 Q1 | 18,925,568 | $38,103,347 | -$235,866 | $2.01 | 30 |
| 2022 Q4 | 19,073,085 | $59,889,323 | -$487,249 | $3.14 | 34 |
| 2022 Q3 | 19,155,756 | $95,971,150 | -$622,456 | $5.01 | 32 |
| 2022 Q2 | 19,268,307 | $108,868,066 | +$80,651,752 | $5.65 | 31 |
| 2022 Q1 | 5,023,218 | $20,194,830 | -$472,028 | $4.02 | 24 |
| 2021 Q4 | 5,050,150 | $22,018,742 | -$3,581,466 | $4.36 | 30 |
| 2021 Q3 | 6,667,024 | $60,849,825 | -$2,869,071 | $9.14 | 34 |
| 2021 Q2 | 6,863,681 | $55,113,000 | -$6,262,171 | $8.02 | 37 |
| 2021 Q1 | 7,560,152 | $87,618,000 | -$11,847,478 | $11.59 | 49 |
| 2020 Q4 | 8,595,912 | $97,990,000 | +$10,187,248 | $11.40 | 43 |
| 2020 Q3 | 7,656,403 | $85,729,000 | +$6,831,952 | $11.18 | 39 |
| 2020 Q2 | 7,037,339 | $79,798,000 | +$79,779,857 | $11.34 | 43 |